on ABIVAX (EPA:ABVX)
Abivax submits its financial reports to French and American regulators
The biotechnology company Abivax announced the filing of its 2025 Universal Registration Document with the French Financial Markets Authority (AMF) and its Annual Report (20-F) with the U.S. Securities and Exchange Commission (SEC). This filing, completed on March 23, 2026, includes detailed financial information and corporate governance reports.
Abivax, which specializes in developing treatments for chronic inflammatory diseases, also provided its auditors' reports. These documents are available online on the websites of Abivax, the AMF (French Financial Markets Authority), and the SEC (Security and Investment Company), making them easily accessible to investors and stakeholders.
R. E.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all ABIVAX news